Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Co.'s primary drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1, a type of genomic alteration and oncogenic driver, and other receptor tyrosine-protein kinase erbB- (HER3), genomically defined cancers. Co. is also evaluating opportunities for pipeline expansion including prioritizing additional targeted therapy approaches in tumor types defined by genomic driver alterations. We show 7 historical shares outstanding datapoints in our coverage of ELEV's shares outstanding history.
Understanding the changing numbers of ELEV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ELEV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ELEV by allowing them to research ELEV shares outstanding history
as well as any other stock in our coverage universe. |
Free ELEV Email Alerts:
Video: Shares Outstanding Importance
